Physician profile
Reema L Habiby
NPI 1033291182
$13,406.22
in general payments reported to CMS, 2019-2025
11 companies · $9,017 in 2025
The $9,017 reported for 2025 was more than what 88% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2021: $283 · 2023: $302 · 2024: $3,294 · 2025: $9,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,958 · Honoraria: $3,180 · Food and Beverage: $378 · Education: $59.50 · Travel and Lodging: $38.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,957.50 |
| Honoraria | $3,180.00 |
| Food and Beverage | $377.97 |
| Education | $59.50 |
| Travel and Lodging | $38.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $12,251.97 | 2024-2025 | Fensolvi, Jatenzo |
| Pfizer INC. | $302.00 | 2023 | |
| Novo Nordisk INC | $250.36 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $135.00 | 2019 | |
| Senseonics, Incorporated | $124.00 | 2019 | |
| Amarin Pharma, INC. | $106.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.28 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $71.58 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $59.50 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Habiby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.